{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:07:23Z","timestamp":1753877243537,"version":"3.41.2"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG040146"],"award-info":[{"award-number":["R01AG040146"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study examined the effects of the comprehensive medication review of Medicare medication therapy management programs on opioid overuse among Medicare beneficiaries.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective study analyzed Medicare data from 2016 to 2017. The intervention group included Medicare beneficiaries who newly received comprehensive medication review in 2017; the control group referred to patients who met the general eligible criteria for the medication therapy management program but did not enroll in 2016 or 2017. Propensity score matching was performed to increase characteristic compatibility between the intervention and control groups. Three measures of opioid overuse were analyzed: use of opioids at a high dosage, use of opioids from multiple providers, and concurrent use of opioids and benzodiazepines. The effects of comprehensive medication review on opioid overuse were analyzed with a multivariate logistic regression with an interaction term between the receipt of comprehensive medication review and the year 2017.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key Findings<\/jats:title>\n                  <jats:p>The proportion of concurrent use of opioids and benzodiazepines declined at a greater rate among the recipients (2.21%) than non-recipients (1.55%) of the comprehensive medication review. In the adjusted analysis, the odds ratio of no concurrent use of opioids and benzodiazepines was 5% higher (1.05; 95% confidence interval = 1.02\u20131.09) among recipients than non-recipients. These significant findings were not found for the other two measures of opioid overuse.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Comprehensive medication review is associated with reduced concurrent use of opioids and benzodiazepines among Medicare beneficiaries. Such service should be incorporated into the current approaches for addressing the opioid epidemic.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jphsr\/rmae002","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T20:08:54Z","timestamp":1709150934000},"source":"Crossref","is-referenced-by-count":0,"title":["Effects of comprehensive medication review on opioid overuse among medicare beneficiaries"],"prefix":"10.1093","volume":"15","author":[{"given":"Yongbo","family":"Sim","sequence":"first","affiliation":[{"name":"Department of Economics, City University of New York , New York, NY , United States"},{"name":"Department of Clinical Pharmacy & Translational Science, University of Tennessee Health Science Center College of Pharmacy , Memphis, TN , United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clayton F","family":"Hausberger","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center College of Pharmacy , Memphis, TN , United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3929-6227","authenticated-orcid":false,"given":"Junling","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy & Translational Science, University of Tennessee Health Science Center College of Pharmacy , Memphis, TN , United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"2024031906121564300_CIT0001","first-page":"125","article-title":"Moving beyond pain as the Fifth vital sign and patient satisfaction scores to improve pain care in the 21st century","volume-title":"Pain Manag Nurs","author":"Scher","year":"2018"},{"article-title":"Treatments for acute pain: a systematic review. Comparative Effectiveness Review No. 240","year":"2020","author":"Chou","key":"2024031906121564300_CIT0002"},{"key":"2024031906121564300_CIT0003","first-page":"1","article-title":"CDC Clinical Practice Guideline for prescribing opioids for pain \u2013 United States, 2022","volume-title":"MMWR Recomm Rep","author":"Dowell","year":"2022"},{"article-title":"Opioid treatments for chronic pain. Comparative effectiveness review No. 229","year":"2020","author":"Chou","key":"2024031906121564300_CIT0004"},{"author":"Pharmacy Quality Alliance","key":"2024031906121564300_CIT0005","article-title":"Measures overview"},{"key":"2024031906121564300_CIT0006","first-page":"796","article-title":"High-risk use by patients prescribed opioids for pain and its role in overdose deaths","volume-title":"JAMA Intern Med","author":"Baumblatt","year":"2014"},{"key":"2024031906121564300_CIT0007","first-page":"j760","article-title":"Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis","volume-title":"BMJ","author":"Sun","year":"2017"},{"key":"2024031906121564300_CIT0008","first-page":"829","article-title":"Cost of prescription drug-related morbidity and mortality","volume-title":"Ann Pharmacother","author":"Watanabe","year":"2018"},{"key":"2024031906121564300_CIT0009","first-page":"580","article-title":"Comprehensive medication review service by embedded pharmacists in primary care: innovations and impact","volume-title":"J Am Pharm Assoc (2003)","author":"Yoo","year":"2022"},{"key":"2024031906121564300_CIT0010","first-page":"1162","article-title":"Medication therapy management programs: promises and pitfalls","volume-title":"J Manag Care Spec Pharm","author":"Ai","year":"2014"},{"year":"2003","author":"Medicare Prescription Drug, Improvement, and Modernization Act of 2003","key":"2024031906121564300_CIT0011"},{"key":"2024031906121564300_CIT0012","first-page":"243","article-title":"Evolution of the medicare part D medication therapy management program from inception in 2006 to the present","volume":"12","author":"Gray","year":"2019","journal-title":"Am Health Drug Benefits"},{"year":"2021","key":"2024031906121564300_CIT0013"},{"article-title":"Medication Therapy Management in Chronically Ill Populations: Final Report","year":"2013","author":"Perlroth","key":"2024031906121564300_CIT0014"},{"key":"2024031906121564300_CIT0015","first-page":"324","article-title":"Improving chronic disease outcomes through medication therapy management in federally qualified health centers","volume-title":"J Prim Care Community Health","author":"Rodis","year":"2017"},{"author":"Centers for Medicare & Medicaid Services","key":"2024031906121564300_CIT0016","article-title":"Announcement of Calendar Year (CY) 2015 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter"},{"author":"Health Resources & Services Administration","key":"2024031906121564300_CIT0017","article-title":"Area Health Resources Files"},{"author":"Research Data Assistance Center","key":"2024031906121564300_CIT0018"},{"author":"Research Data Assistance Center","key":"2024031906121564300_CIT0019","article-title":"Medicare Master Beneficiary Summary File (MBSF) base"},{"author":"Research Data Assistance Center","key":"2024031906121564300_CIT0020","article-title":"Part D Event (PDE) File"},{"author":"Research Data Assistance Center","key":"2024031906121564300_CIT0021","article-title":"Part D Medication Therapy Management Data file"},{"article-title":"Technical Specifications for PQA-Endorsed Measures","year":"2018","author":"Pharmacy Quality Alliance","key":"2024031906121564300_CIT0022"},{"article-title":"CY 2016 medication therapy management program guidance and submission instructions","year":"2015","author":"Centers for Medicare & Medicaid Services","key":"2024031906121564300_CIT0023"},{"article-title":"2016 Medicare Part D medication therapy management (MTM) programs","year":"2016","author":"Centers for Medicare & Medicaid Services","key":"2024031906121564300_CIT0024"},{"article-title":"2017 Medicare Part D medication therapy management (MTM) programs","year":"2017","author":"Centers for Medicare & Medicaid Services","key":"2024031906121564300_CIT0025"},{"key":"2024031906121564300_CIT0026","first-page":"142","article-title":"Characteristics of older adults who meet the annual prescription drug expenditure threshold for Medicare medication therapy management programs","volume-title":"J Manag Care Pharm","author":"Daniel","year":"2007"},{"key":"2024031906121564300_CIT0027","first-page":"1057","article-title":"A comparison of 12 algorithms for matching on the propensity score","volume-title":"Stat Med","author":"Austin","year":"2014"},{"key":"2024031906121564300_CIT0028","volume-title":"Pharmacoepidemiology","author":"Strom","year":"2005","edition":"4th ed"},{"key":"2024031906121564300_CIT0029","first-page":"1273","article-title":"The behavioral model for vulnerable populations: application to medical care use and outcomes for homeless people","volume":"34","author":"Gelberg","year":"2000","journal-title":"Health Serv Res"},{"key":"2024031906121564300_CIT0030","first-page":"e1","article-title":"Validity of race and ethnicity codes in Medicare administrative data compared with gold-standard self-reported race collected during routine home health care visits","volume-title":"Med Care","author":"Jarrin","year":"2020"},{"year":"2014","author":"Centers for Medicare & Medicaid Services","key":"2024031906121564300_CIT0031"},{"author":"Centers for Medicare & Medicaid Services","key":"2024031906121564300_CIT0032"},{"key":"2024031906121564300_CIT0033","first-page":"25","article-title":"Preliminary investigation of pharmacist-delivered, direct-to-provider interventions to reduce co-prescribing of opioids and benzodiazepines among a medicare population","volume-title":"Pharmacy (Basel)","author":"Bingham","year":"2020"},{"key":"2024031906121564300_CIT0034","first-page":"2913","article-title":"Pharmacist interventions to deprescribe opioids and benzodiazepines in older adults: a rapid review","volume-title":"Res Social Adm Pharm","author":"Niznik","year":"2022"},{"key":"2024031906121564300_CIT0035","first-page":"2216","article-title":"Pharmacist-led multidisciplinary approach","volume-title":"Arthritis & Rheumatology","author":"Farrell","year":"2021"},{"key":"2024031906121564300_CIT0036","first-page":"e000635","article-title":"Opioid stewardship: implementing a proactive, pharmacist-led intervention for patients coprescribed opioids and benzodiazepines at an urban academic primary care centre","volume-title":"BMJ Open Qual","author":"Tilli","year":"2020"},{"article-title":"Medication therapy management interventions in outpatient settings [Internet]","year":"2014","author":"Viswanathan","key":"2024031906121564300_CIT0037"},{"key":"2024031906121564300_CIT0038","first-page":"367","article-title":"Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention\u2019s 2016 Opioid Guideline","volume-title":"Ann Intern Med","author":"Bohnert","year":"2018"},{"key":"2024031906121564300_CIT0039","first-page":"13","article-title":"A brief history of the opioid epidemic and strategies for pain medicine","volume-title":"Pain Ther","author":"Jones","year":"2018"},{"key":"2024031906121564300_CIT0040","first-page":"1208","article-title":"Opioid and Benzodiazepine Coprescribing in the United States before and after US Food and Drug Administration Boxed Warning","volume-title":"JAMA Psychiatry","author":"Zhang","year":"2019"},{"key":"2024031906121564300_CIT0041","first-page":"108350","article-title":"The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017","volume-title":"Drug Alcohol Depend","author":"Florence","year":"2021"},{"key":"2024031906121564300_CIT0042","first-page":"2115","article-title":"US Emergency Department visits for outpatient adverse drug events, 2013-2014","volume-title":"JAMA","author":"Shehab","year":"2016"},{"article-title":"National trends in high-dose chronic opioid utilization among dually eligible and Medicare-only beneficiaries (2006\u20132015)","volume-title":"Data Analysis Brief: Center for Medicare","author":"Anderson","key":"2024031906121564300_CIT0043"},{"key":"2024031906121564300_CIT0044","first-page":"316","article-title":"Multicomorbidity of chronic diseases and substance use disorders and their association with hospitalization: results from electronic health records data","volume-title":"Drug Alcohol Depend","author":"Wu","year":"2018"},{"key":"2024031906121564300_CIT0045","first-page":"E157","article-title":"Opioid-related hospitalization and its association with chronic diseases: findings from the National Inpatient Sample, 2011-2015","volume-title":"Prev Chronic Dis","author":"Rajbhandari-Thapa","year":"2019"},{"key":"2024031906121564300_CIT0046","first-page":"1011","article-title":"Concurrent opioid and benzodiazepine utilization patterns and predictors among community-dwelling adults in the United States","volume-title":"Psychiatr Serv","author":"Vadiei","year":"2020"},{"key":"2024031906121564300_CIT0047","first-page":"563","article-title":"Vital signs: variation among States in prescribing of opioid pain relievers and benzodiazepines \u2013 United States, 2012","volume":"63","author":"Paulozzi","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024031906121564300_CIT0048","first-page":"35","article-title":"Primary care providers\u2019 perspective on prescribing opioids to older adults with chronic non-cancer pain: a qualitative study","volume-title":"BMC Geriatr","author":"Spitz","year":"2011"}],"container-title":["Journal of Pharmaceutical Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jphsr\/article-pdf\/15\/1\/rmae002\/57011206\/rmae002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jphsr\/article-pdf\/15\/1\/rmae002\/57011206\/rmae002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T06:14:38Z","timestamp":1710828878000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jphsr\/article\/doi\/10.1093\/jphsr\/rmae002\/7615764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jphsr\/rmae002","relation":{},"ISSN":["1759-8893"],"issn-type":[{"type":"electronic","value":"1759-8893"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2024,2,28]]},"article-number":"rmae002"}}